Starting IFN- -1a therapy at the time of the first demyelinating event beneficial in patients at high risk of MS

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1258, 2000-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patients with multiple sclerosis (MS) who receive interferon (IFN)- -1a [`Avonex']

By  

Inpharma, Vol. 1, Iss. 1330, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Patients with multiple sclerosis (MS) who receive interferon (IFN)- -1a [`Avonex']

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 355, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Combination therapy is preferred for the first-line treatment of hypertension in high-risk patients

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 7, 2010-07 ,pp. : 17-20

Adis International

Access to resources Recommend Favorite

Drug-eluting stents beneficial for high-risk patients

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

IFN- -1a, IFN- -1b, glatiramer acetate not warranted in MS

By  

Inpharma, Vol. 1, Iss. 1462, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite